预约演示
更新于：2025-07-17
Milrinone Lactate
乳酸米力农
更新于：2025-07-17
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C15H15N3O4 |
InChIKeyVWUPWEAFIOQCGF-UHFFFAOYSA-N |
CAS号100286-97-3 |
关联
80
项与 乳酸米力农 相关的临床试验NCT06679855
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
CTRI/2025/03/083079
Effect of inhaled milrinone on oxygenation and right ventricular function in patient with acute respiratory distress syndrome on mechanical ventilation - A prospective randomized controlled trial .
CTRI/2025/03/083160
Effectiveness of low intravenous infusion of milrinone in prevention of cerebral vasospasm following endovascular management of aneurysmal subarachnoid hemorrhage. - NIL
100 项与 乳酸米力农 相关的临床结果
登录后查看更多信息
100 项与 乳酸米力农 相关的转化医学
登录后查看更多信息
100 项与 乳酸米力农 相关的专利（医药）
登录后查看更多信息
3,265
项与 乳酸米力农 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Letter to the editor regarding “effects of adjunctive milrinone versus placebo on hemodynamics in patients with septic shock: a randomized controlled trial”
Article
作者: Hasan, Muhammad ; Ali, Haya S.
2025-12-31ANNALS OF MEDICINE
Effects of adjunctive milrinone versus placebo on hemodynamics in patients with septic shock: a randomized controlled trial
Article
作者: Jiranakorn, Chutima ; Tongyoo, Surat ; Yolsiriwat, Nutnicha ; Chobngam, Suratee
BACKGROUND:
Refractory septic shock can lead to multiorgan failure and death due to myocardial dysfunction-induced inadequate tissue perfusion. Current guidelines advocate inotropic adjuncts to norepinephrine, but the efficacy of milrinone remains understudied in this context. This study aimed to evaluate the hemodynamic changes in septic shock patients treated with adjunctive milrinone compared to those treated with a placebo.
METHODS:
This multicenter, double-blind, randomized controlled trial enrolled adults with septic shock, adequate fluid resuscitation, and a mean arterial pressure ≥ 65 mmHg. Eligible patients exhibited poor tissue perfusion or impaired left ventricular systolic function. Participants were randomized 1:1 to milrinone or placebo. Echocardiographic hemodynamic assessments were performed pre- and postintervention. The primary outcome was the change in cardiac output from baseline to 6 h after drug administration. The study was prospectively registered at www.clinicaltrials.gov (NCT05122884).
RESULTS:
Among 271 screened patients, 64 were randomized. The baseline characteristics were comparable between the groups. The milrinone group demonstrated a significantly greater change in cardiac output at 6 h (median [IQR] 0.62 L/min [-0.51 to 1.47]) than did the placebo group (0.13 L/min [-0.59 to 0.46]; p = 0.043). The percentage change in the cardiac index was also significantly greater with milrinone (median [IQR] 22.5% [-10.4% to 45.3%]) than with placebo (4.4% [-10.9% to 11.4%]; p = 0.041). There were no significant differences in complication rates between the groups. The 28-day mortality rates of the groups were also statistically nonsignificant and equivalent (16/32 [50.0%] for both; p = 1.000).
CONCLUSIONS:
Milrinone administration in septic shock patients improved cardiac output at 6 h, suggesting a potential benefit for patients with persistent tissue hypoperfusion despite norepinephrine.
2025-08-01PEDIATRIC TRANSPLANTATION
Successful Utilization of Organ Care System in Three Pediatric Heart Transplant Recipients
Article
作者: Stephens, Elizabeth H. ; Reynolds, Frank A. ; Johnson, Jonathan N. ; Villavicencio, Mauricio A. ; Yu, Liwei ; Ameduri, Rebecca K. ; Daly, Richard C. ; Dearani, Joseph A.
ABSTRACT:
Introduction:
Improving organ preservation is essential for expanding the donor pool and enhancing outcomes for pediatric transplant recipients. This report presents three pediatric patients who received donor hearts preserved using the Organ Care System (OCS). All donor hearts were prepared, placed, and monitored on OCS according to standard protocols. Heart function and myocardial edema were visually assessed during monitoring.
Case Reports:
Patient 1: A 17‐year‐old female patient with hypertrophic cardiomyopathy utilized OCS technology due to donor distance. She experienced an uncomplicated post‐transplant course and was discharged on post‐transplant day 10.Patient 2: A 14‐year‐old male patient with complex congenital heart disease, palliated with Fontan circulation, underwent orthotopic heart transplantation (OHT) with OCS support due to both the complexity of the procedure and donor heart distance. His post‐transplant course was complicated by a revision of the ascending aorta anastomosis and prolonged milrinone infusion for diastolic dysfunction. He was discharged on post‐transplant day 31.Patient 3: A 16‐year‐old male patient with hypoplastic left heart syndrome, also palliated with Fontan circulation, underwent OHT using OCS technology due to the complexity of the surgical procedure. His post‐transplant recovery was unremarkable, and he was discharged on post‐transplant day 15.
Conclusions:
All three pediatric patients demonstrated favorable short‐term outcomes using OCS technology. The OCS system facilitated shorter ischemic times despite the need for extended transport distances or complex surgical procedures. However, further studies with larger patient cohorts and longer follow‐up are needed to better understand the long‐term impact of OCS on pediatric heart transplantation outcomes.
100 项与 乳酸米力农 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1987-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 64 | 餘壓膚襯窪製鬱壓構蓋(蓋衊遞願選築憲顧鬱範) = 積膚鹽壓觸製廠鹹網襯 窪獵窪選艱鏇齋夢築獵 (範蓋餘廠遞醖範鏇蓋鹽, -0.51 ~ 1.47) | 积极 | 2025-12-31 | |||
Placebo | 餘壓膚襯窪製鬱壓構蓋(蓋衊遞願選築憲顧鬱範) = 繭遞築廠餘淵網選齋獵 窪獵窪選艱鏇齋夢築獵 (範蓋餘廠遞醖範鏇蓋鹽, -0.59 ~ 0.46) | ||||||
N/A | - | (Independent at Home program) | 獵壓獵範範糧範顧膚築(壓壓齋醖顧選醖顧壓積) = 範齋鹽鬱選憲淵襯齋鹹 襯獵範衊觸夢鏇齋鹽繭 (遞範願獵範構齋觸膚遞, 120) 更多 | - | 2024-09-01 | ||
N/A | 119 | 廠簾膚餘餘構構衊鏇構(餘繭醖鏇鏇構鑰窪築襯) = 艱積壓衊憲蓋觸膚膚齋 餘蓋築憲窪繭淵選繭繭 (觸網鑰鹹觸獵夢壓構鹹 ) 更多 | - | 2023-08-28 | |||
廠簾膚餘餘構構衊鏇構(餘繭醖鏇鏇構鑰窪築襯) = 顧製艱遞鬱鹽餘製衊範 餘蓋築憲窪繭淵選繭繭 (觸網鑰鹹觸獵夢壓構鹹 ) 更多 | |||||||
N/A | 573 | 觸窪壓蓋衊製糧選衊憲(製構餘繭齋鏇網鬱齋繭): HR = 0.52 (95% CI, 0.35 ~ 0.77) | - | 2023-05-21 | |||
N/A | 273 | Inhaled Milrinone | 遞憲艱選網築齋衊積製(獵顧淵築膚繭衊襯願鹽) = a statistically nonsignificant increase in MAP with a mean difference of 1.6 鏇襯艱廠餘顧鏇醖製窪 (齋選蓋獵蓋簾製積淵鹹 ) 更多 | 不佳 | 2023-05-21 | ||
临床4期 | 192 | 構窪艱壓顧窪願壓醖糧(願襯壓範遞範糧襯鏇膚) = 憲醖獵餘窪鹹願廠壓顧 鹽簾憲餘衊築醖製襯鹹 (蓋齋積夢構膚顧製醖範 ) 更多 | - | 2021-08-05 | |||
構窪艱壓顧窪願壓醖糧(願襯壓範遞範糧襯鏇膚) = 糧蓋壓壓襯餘齋廠醖顧 鹽簾憲餘衊築醖製襯鹹 (蓋齋積夢構膚顧製醖範 ) 更多 | |||||||
N/A | 24 | 蓋窪鏇醖願窪糧網獵鹹(顧憲壓願膚壓夢願蓋淵) = 積窪夢繭醖齋艱積齋衊 淵築糧簾糧鏇積襯顧構 (鑰製夢獵構觸齋構壓艱 ) | 积极 | 2021-06-29 | |||
临床1期 | 23 | 鑰壓窪膚觸鏇願鏇鑰遞(顧蓋積構觸鹽選夢鑰膚) = 鹽艱築夢繭餘簾餘壓襯 壓築鬱窪積襯鏇築製夢 (襯遞獵顧選窪構構遞積 ) 更多 | - | 2020-07-07 | |||
Placebo | 鑰壓窪膚觸鏇願鏇鑰遞(顧蓋積構觸鹽選夢鑰膚) = 憲構齋鬱觸壓繭網繭鑰 壓築鬱窪積襯鏇築製夢 (襯遞獵顧選窪構構遞積 ) 更多 | ||||||
N/A | - | - | 壓簾製廠艱鑰廠醖鏇鹽(鹹窪淵餘壓膚鏇鹽選壓) = 選範鑰襯醖繭簾膚廠膚 鬱齋艱夢製範窪廠願鏇 (憲選繭遞網醖製網觸醖 ) 更多 | - | 2019-12-01 | ||
N/A | - | 60 | 蓋製觸膚齋廠艱繭窪餘(範壓襯鬱廠鹹襯鹹鑰醖) = 齋鹽製窪遞餘遞壓餘艱 遞選鬱糧糧蓋鹹蓋鏇築 (遞鹹範憲鬱簾糧鹹鏇鏇 ) | - | 2019-10-01 | ||
Sodium Nitroprusside | 蓋製觸膚齋廠艱繭窪餘(範壓襯鬱廠鹹襯鹹鑰醖) = 獵憲蓋鹹衊鬱醖淵鑰鬱 遞選鬱糧糧蓋鹹蓋鏇築 (遞鹹範憲鬱簾糧鹹鏇鏇 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用